Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. News
  7. Summary
    ILMN   US4523271090


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina : EU Court ruling on Altice provides boost for antitrust regulators

09/22/2021 | 06:25am EDT

BRUSSELS, Sept 22 (Reuters) - EU antitrust regulators received a boost from Europe's second-highest court on Wednesday as it upheld a record fine against French telecom company Altice for jumping the gun on its bid for PT Portugal.

The decision empowers the European Commission as it investigates U.S. life sciences company Illumina for closing its takeover of cancer detection test-maker Grail without first securing EU approval.

Acting before approval, or jumping the gun, is a major offence under EU merger rules, with fines for violations of up to 10% of a company's global turnover. Altice's 125-million-euro ($146.7 million) fine was the biggest the European Commission has imposed to date for such an offence.

The Luxembourg-based General Court reduced the fine by 6.22 million euros, but did not cancel it.

The judges said in their ruling the reduction was because Altice informed the Commission of the transaction before the share purchase agreement was signed and that "immediately after that signing, it sent to the Commission a case team allocation request relating to its file".

The Commission in its 2018 decision said Altice had breached EU merger rules by exercising decisive influence and veto rights over the Portuguese company before securing regulatory clearance for the deal.

Altice can appeal to the EU Court of Justice, Europe's highest, but only on points of law.

In 2017, Facebook was handed a 110-million-euro fine for giving misleading information during the EU review of its WhatsApp bid. The sanctions did not affect both deals, which were approved.

The case is T-425/18 Altice Europe v Commission.

($1 = 0.8522 euros) (Reporting by Foo Yun Chee; editing by Barbara Lewis)

© Reuters 2021
All news about ILLUMINA, INC.
10/15INSIDER SELL : Illumina
10/15ILLUMINA : Ragusa succeeds Hans Bishop, who will continue to serve as Advisor to the CEO t..
10/15ILLUMINA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
10/15ILLUMINA : Appoints Bob Ragusa as GRAIL's CEO
10/13ILLUMINA : to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
10/12ILLUMINA : European Commission To Make Decision On Illumina's GRAIL Acquisition By Februar..
10/12ILLUMINA : EU antitrust regulators resume Illumina, Grail probe, decision due by Feb. 4
09/30ILLUMINA : Expands Genomics Operations to Colombia, Mexico
09/30ILLUMINA : Expands Presence in Latin America
09/30Illumina Expands Presence in Latin America
More news
Analyst Recommendations on ILLUMINA, INC.
More recommendations
Financials (USD)
Sales 2021 4 344 M - -
Net income 2021 692 M - -
Net cash 2021 1 689 M - -
P/E ratio 2021 88,2x
Yield 2021 -
Capitalization 64 248 M 64 248 M -
EV / Sales 2021 14,4x
EV / Sales 2022 12,5x
Nbr of Employees 7 825
Free-Float 74,8%
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Last Close Price 410,53 $
Average target price 455,00 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Francis A. deSouza President, Chief Executive Officer & Director
Sam A. Samad Chief Financial Officer & Senior Vice President
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors